Personalis to Participate at the 22nd Annual Needham Virtual Healthcare Conference
Get Alerts PSNL Hot Sheet
Join SI Premium – FREE
FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19 at 3:00 p.m. Eastern Time.
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230405005339/en/
Investor Relations Contact:
Caroline Corner
[email protected]
415-202-5678
Media Contact:
Jennifer Temple
[email protected]
www.personalis.com
650-752-1300
Source: Personalis, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Priority Courier Experts Acquires Priority Dispatch, Inc. and Diamond Expedited, Deepening Midwest Presence
- Vital Energy Announces Amendments to Existing Credit Facility and Additional Credit Facility
- OutSystems Ranks #1 in G2’s Enterprise Grid® Report for AI App Builders, Named a Leader in Agentic AI
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Needham & Company, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share